Akari Therapeutics (AKTX) Accumulated Expenses (2014 - 2026)

Akari Therapeutics (AKTX) has 13 years of Accumulated Expenses data on file, last reported at $888000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 122.0% year-over-year to $888000.0; the trailing twelve-month figure through Mar 2026 stood at $888000.0 (up 122.0% YoY), and the FY2025 full-year result was $2.3 million, up 420.44% from the prior year.
• Accumulated Expenses eased to $888000.0 in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q4 2022 to a low of $400000.0 in Q1 2025.
• A 5-year average of $1.5 million and a median of $1.5 million in 2024 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 420.44% in 2025, while the deepest fall reached 76.7% in 2025.
• Tracing AKTX's Accumulated Expenses over 5 years: stood at $3.1 million in 2022, then sank by 50.25% to $1.6 million in 2023, then tumbled by 71.26% to $450000.0 in 2024, then soared by 420.44% to $2.3 million in 2025, then sank by 62.08% to $888000.0 in 2026.
• Business Quant data shows AKTX's Accumulated Expenses at $888000.0 in Q1 2026, $2.3 million in Q4 2025, and $607000.0 in Q3 2025.